Overview

Cognitive and Behavioral Effects of Lacosamide

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective: Null hypothesis: A 24-week trial of adjunctive Lacosamide does not produce a decline in cognitive, mood or quality of life measures. To determine the cognitive and behavioral side effects of lacosamide in patients with partial epilepsy and follow them for a period of 24 weeks using a neuropsychological test battery drawing on tests commonly used and designed to maximize sensitivity to drug effects. Secondary Objectives: To determine if any significant changes in cognitive, mood or quality of life measures are dependent upon changes in seizure severity, neurotoxicity, adverse events, or Lacosamide dosage.
Phase:
Phase 4
Details
Lead Sponsor:
Evan Fertig
Collaborator:
UCB Pharma
Treatments:
Lacosamide